Clinical Pipeline

Clinical Pipeline

Clinical trials for the treatment of HPV-, PSA- and HER2-associated cancers.

Axalimogene filolisbac (ADXS-HPV), Advaxis’s lead drug candidate, is in clinical trials for HPV-associated cancers. In addition, the company has a preclinical program with 20 distinct immunotherapies in development for cancers and infectious diseases.

Advaxis Clinical Pipeline

Indication Phase 1 Phase 2 Phase 3 Trials

Axalimogene filolisbac (ADXS-HPV)

Cervical* AIM2CERV

Cervical*
Metastatic Cervical

Phase 2

Cervical*
Metastatic - GOG

Phase 2 View Trial

Cervical*
Combo with MEDI 47361

Phase 1/2 View Trial

Cervical*
Metastatic Single Arm High Dose

Phase 1/2 View Trial

Head and Neck*
Neoadjuvant Window of Opportunity - Mount Sinai

Phase 2 View Trial

Head & Neck*
Metastatic - Combo with MEDI 47361

Phase 1/2 View Trial

Anal*
Adjuvant Single Arm in High Risk - Brown University

Phase 2 View Trial

Anal* Metastatic

Phase 2

ADXS-PSA

Prostate
Combo with Keytruda®2

Phase 1/2 View Trial

ADXS-HER2

HER2 Overexpressing Tumors
(IND Approved)

Phase 1
Completed In Progress Planned

* Orphan Drug Designation Granted

  1. Partnership with Medimmune (AZ)
  2. Partnership with Merck